RESEARCH TRIANGLE PARK, N.C. – Quoting several Wall Street analysts, is reporting that the Food and Drug Administration could approve a new breast cancer drug from GlaxoSmithKline on Tuesday.

The drug, which has been granted fast-track status by the FDA, is called tykerb. It targets women who have been unsuccessfully treated with another drug known as Herceptin. The drugs target as many as 30 percent of women who suffer from breast cancer.

If approved tykerb would be used in conjunction with chemotherapy.
"There’s still some nervousness around the FDA decision simply because of the FDA’s lack of predictability in recent times," one analyst told "Despite expectations, the FDA could still ruin things."